Metronidazole Braun

Metronidazole, the active ingredient in Metronidazole Braun, is a nitroimidazole antibiotic presented as an injectable solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in adult patients.

GNH USA supplies Metronidazole Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmacopeial standards and is manufactured under GMP conditions, ensuring consistent quality for acute care settings. It is distributed through GNH USA's regulated supply chain, meeting the requirements of health authorities in multiple jurisdictions.

Metronidazole is employed to treat infections caused by anaerobic bacteria and susceptible protozoa.

Anaerobic bacterial infections: eradicates mixed anaerobic flora in intra‑abdominal and soft‑tissue infections. Intra‑abdominal infections: reduces infection severity following perforated viscus or postoperative contamination. Pelvic inflammatory disease: targets anaerobic organisms contributing to PID, aiding clinical resolution. Bacterial vaginosis: restores normal vaginal flora by eliminating Gardnerella and other anaerobes. Trichomoniasis: effective against Trichomonas vaginalis, relieving symptoms and preventing transmission. Clostridioides difficile infection: used as part of therapy to suppress toxin‑producing anaerobes.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Metallic taste - Headache - Diarrhea - Abdominal pain - Dizziness

Serious or Rare Side Effects: - Seizures - Peripheral neuropathy - Severe allergic reactions (anaphylaxis, skin rash) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic toxicity (elevated transaminases, hepatitis) - Neutropenia or agranulocytosis

Before initiating Metronidazole Braun, clinicians should consider several safety precautions. - Assess renal function: adjust dosing or avoid use in severe renal impairment. - Monitor hepatic enzymes: watch for signs of liver injury during therapy. - Avoid in known hypersensitivity: discontinue immediately if allergic reaction occurs. - Use with caution in pregnancy: risk to fetus is unclear; weigh benefits against potential harm. - Limit duration of therapy: prolonged use may increase resistance and toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Alcohol: may cause a disulfiram‑like reaction with flushing, nausea, and tachycardia. - Warfarin: increased anticoagulant effect, raising risk of bleeding. - Lithium: concurrent use can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenobarbital: may reduce metronidazole levels, decreasing effectiveness. - Erythromycin: can raise metronidazole concentrations, requiring monitoring.